ARPI: Abiraterone

Phase 2Small molecule

Novartis

ARPI: Abiraterone is one of 13 small molecule programs targeting First-line. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-LineActive, not recruiting

First-LinePhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in First-Line

#DrugCompanyPhaseTrials

COLUMVI

Roche

Phase 2

1 2

Polivy

Roche

Phase 2

1 3

Brukinsa

BBeOne Medicines

Phase 2

1 4

AAA617

Novartis

Phase 2

1 5

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 6

Targeted Therapy

FFudan University

Phase 2

1 7

PM8002

BBiotheus Inc.

Phase 2

1 8

Delstrigo

PProfessor Francois Venter

Phase 3

1 9

EGFR-TK Inhibitor

LLuBing

Phase 2

1 10

ARPI: Abiraterone

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

First-Line

NCT06894511

Clinical

Trials by Indication[1]

First-line1 trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06894511·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARPI: Abiraterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARPI: Abiraterone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARPI: Abiraterone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

ARPI: Abiraterone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

First-line1 trial

References

Drug Info

Quick Facts

Related News